Amylyx Pharmaceuticals, Inc. (AMLX) insider trading
Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 12, 2026.
- Filings shown
- 22
- Open-market buys
- 1
- Open-market sells
- 21
- Buys, 10b5-1 box not checked
- 1 of 1
Counts cover the 22 most recent Form 4 filings Tradune holds for AMLX (filed May 26 – Nov 12, 2026); the score below covers only the trailing 90 days (0 buys, 19 sells). SEC EDGAR Form 4 filings for AMLX last checked Nov 22, 2026, 09:00 UTC; the latest AMLX filing Tradune holds was filed Nov 12, 2026. This is not guaranteed to be the complete record — see AMLX's full Form 4 filing history on SEC EDGAR.
Open-market activity, last 90 days
Purchases (Form 4 code P) and sales (code S) on the 10 filings Tradune holds for AMLX filed Sep 2 – Nov 12, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.
19 open-market sales by Rule 10b5-1 checkbox
- On filings with the 10b5-1 box checked
- 9 sales· 270,000 sh
- checkbox disclosed
- On filings with the box not checked
- 10 sales· 91,302 sh
- not proof that no plan exists
- Not comparable
- 0 sales· 0 sh
- filed before Apr 1, 2023, or no checkbox value in the filing data
Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.
| Insider | Buys | Sells | Shares bought | Shares sold | Value |
|---|---|---|---|---|---|
| James M. FratesChief Financial Officer | 0 | 6 | — | 50,810 | −$1,557,563 |
| Joshua B. CohenCo-Chief Executive Officer | 0 | 4 | — | 130,464 | −$3,964,182 |
| Justin B. KleeCo-Chief Executive Officer | 0 | 4 | — | 130,464 | −$3,964,102 |
| Camille L. BedrosianChief Medical Officer | 0 | 2 | — | 10,028 | −$324,868 |
| Gina MazzarielloChief Legal Officer | 0 | 2 | — | 9,536 | −$309,506 |
| George M. Milne Jr.Director | 0 | 1 | — | 30,000 | −$830,904 |
Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.
Insider-activity score
0/ 100
Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →
Get alerted when insiders buy the stocks you own
Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.
Free for everyone right now · no card · nothing to buy
How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).
Insider Buying at AMLX
Insiders reported 1 open-market purchase of AMLX between May 26, 2026 and Nov 12, 2026, across 1 distinct buyer. The most recent purchase was reported by Karen Firestone (Director) on May 21, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Recent Form 4 filings
Source: SEC EDGAR Form 4 · transaction codes explained
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise | 20,000 | $6.88 | 253,625 | +8.6% | Nov 10, 2026 |
| Option exercise Stock Option (right to buy) | 20,000 | — | — | — | Nov 10, 2026 |
| Open-market sale 10b5-1 box checked | 7,200 | $30.97 | 233,625 | −3.0% | Nov 10, 2026 |
| Open-market sale 10b5-1 box checked | 12,800 | $30.32 | 240,825 | −5.0% | Nov 10, 2026 |
| Option exercise Stock Option (right to buy) | 20,000 | — | — | — | Nov 9, 2026 |
| Option exercise | 20,000 | $6.88 | 253,625 | +8.6% | Nov 9, 2026 |
| Open-market sale 10b5-1 box checked | 7,700 | $29.39 | 245,925 | −3.0% | Nov 9, 2026 |
| Open-market sale 10b5-1 box checked | 12,300 | $30.11 | 233,625 | −5.0% | Nov 9, 2026 |
† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.
“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box checked | 37,483 | $29.39 | 3,575,573 | −1.0% | Nov 9, 2026 |
| Open-market sale 10b5-1 box checked | 62,517 | $30.11 | 3,513,056 | −1.7% | Nov 9, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box checked | 38,105 | $29.39 | 3,575,018 | −1.1% | Nov 9, 2026 |
| Open-market sale 10b5-1 box checked | 61,895 | $30.11 | 3,513,123 | −1.7% | Nov 9, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box checked | 30,000 | $27.70 | 782,881 | −3.7% | Oct 5, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box not checked | 7,947 | $32.21 | 280,145 | −2.8% | Sep 10, 2026 |
| Open-market sale 10b5-1 box not checked | 2,081 | $33.09 | 278,064 | −0.7% | Sep 10, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box not checked | 1,042 | $33.23 | 233,625 | −0.4% | Sep 10, 2026 |
| Open-market sale 10b5-1 box not checked | 9,768 | $32.27 | 234,667 | −4.0% | Sep 10, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box not checked | 11 | $33.34 | 190,838 | −0.0% | Sep 10, 2026 |
| Open-market sale 10b5-1 box not checked | 9,525 | $32.46 | 190,849 | −4.8% | Sep 10, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box not checked | 919 | $33.15 | 3,613,123 | −0.0% | Sep 10, 2026 |
| Open-market sale 10b5-1 box not checked | 29,545 | $32.16 | 3,614,042 | −0.8% | Sep 10, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box not checked | 1,439 | $33.16 | 3,613,056 | −0.0% | Sep 10, 2026 |
| Open-market sale 10b5-1 box not checked | 29,025 | $32.13 | 3,614,495 | −0.8% | Sep 10, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Option exercise | 25,000 | $1.76 | 91,900 | +37% | Aug 31, 2026 |
| Option exercise | 25,000 | $5.05 | 116,900 | +27% | Aug 31, 2026 |
| Option exercise Stock Option (right to buy) | 25,000 | — | — | — | Aug 31, 2026 |
| Option exercise Stock Option (right to buy) | 25,000 | — | — | — | Aug 31, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award | 22,807 | — | 244,435 | +10% | Aug 18, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award | 60,039 | — | 3,643,520 | +1.7% | Aug 18, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award | 21,284 | — | 200,374 | +12% | Aug 18, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award | 22,807 | — | 288,092 | +8.6% | Aug 18, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award | 60,039 | — | 3,643,587 | +1.7% | Aug 18, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market sale 10b5-1 box checked | 15,000 | $17.61 | 179,090 | −7.7% | Jul 10, 2026 |
| Open-market sale 10b5-1 box checked | 15,000 | $18.32 | 194,090 | −7.2% | Jul 9, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (right to buy) | 24,372 | — | — | — | Jun 4, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (right to buy) | 24,372 | — | — | — | Jun 4, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (right to buy) | 24,372 | — | — | — | Jun 4, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (right to buy) | 24,372 | — | — | — | Jun 4, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (right to buy) | 24,372 | — | — | — | Jun 4, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market purchase 10b5-1 box not checked | 3,800 | $13.51 | 66,900 | +6.0% | May 21, 2026 |
Insider filings reported around the same time
Other companies whose most recent Form 4 was filed closest to AMLX's (Nov 12, 2026).
Frequently asked about AMLX insider activity
How many insiders bought AMLX stock in these Form 4 filings?
1 distinct insider at Amylyx Pharmaceuticals, Inc. reported 1 open-market purchase (Form 4 code P) of AMLX shares between May 26, 2026 and Nov 12, 2026, the most recent filed by Karen Firestone (Director) on May 21, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Who filed the most recent Form 4 for AMLX?
The most recent Form 4 on this page was filed by Joshua B. Cohen (Co-Chief Executive Officer) on Nov 12, 2026, reporting 2 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.
What was the largest open-market AMLX insider sale shown?
The largest open-market sale among the filings shown was 62,517 AMLX shares at $30.11 (about $1,882,149) by Justin B. Klee (Co-Chief Executive Officer) on Nov 9, 2026. Value is shares × the price reported on the Form 4; that Form 4 has the Rule 10b5-1 box checked.
Do the recent AMLX insider purchases have the Form 4 10b5-1 box checked?
No. The one AMLX open-market purchase shown was reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Karen Firestone (Director) on May 21, 2026, 3,800 shares.
New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.
Get insider alerts for AMLX — and your whole portfolio
Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy
This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.
Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.